IL6 and prostate cancer: In prostate cancer, loss of p62 in the stromal fibroblasts impairs mTORC1 activation, which results in a reduced metabolic detoxification capacity and the secretion of the prosurvival inflammatory cytokine IL‐6, which sustains the growth and invasiveness of the neighboring prostate cancer cells 61.